20276 CGT Miami Main Brochure V2.qxp Layout 1 18/10/2017 ......Rubius Therapeutics Robert Smith,...
Transcript of 20276 CGT Miami Main Brochure V2.qxp Layout 1 18/10/2017 ......Rubius Therapeutics Robert Smith,...
22-25 JANUARY 2018 | HYATT REGENCY, MIAMI
THE WORLD'S NUMBER 1 PARTNERING EVENT FOR ADVANCED THERAPIES
Also part of the Phacilitate Leaders Forum
1200+Attendees
400+Organisations
200+Speakers
30+ Countries
Find out more at www.cellandgenetherapyworld.com
MEET OUR VISIONARY SPEAKERS!
Platinum sponsor
Katherine A. High, MD,President and ChiefScientific Officer,Spark Therapeutics
Maria T. Millan, MD,Interim President & CEO,California Institute forRegenerative Medicine(CIRM)
Naomi Aronson, PhD,Executive Director ofClinical Evaluation,Innovation and Policy in theOffice of Clinical Affairs,Blue Cross and BlueShield Association
Avak Kahvejian, PhD,Partner, FlagshipPioneering; ChiefInnovation Officer,Rubius Therapeutics
Robert Smith,Senior Vice President andEarly Commercial Lead,Gene Therapy ResearchUnit,Pfizer, Inc
Kapil Bharti, PhD,Stadtman Investigator, Uniton Ocular Stem Cell &Translational Research(OSCTR),National Eye Institute,NIH
Dr Hans Keirstead,Chief Executive Officer,AIVITA BiomedicalCandidate for USCongress
Timothy Moore,Executive Vice President ofTechnical Operations, Kite Pharma
Dr Pascal TouchonSenior Vice President,Global Head StrategyBD&L; Executive BoardMemberNovartis Oncology
Dr Tim Anderson,Managing Director,Global PharmaceuticalsEquity Research,Sanford C. Bernstein
Dr Greg Russotti,Vice President, TechnicalOperations,Celgene CellularTherapeutics
Dr Anthony Ridgway,Acting Director, Centre forEvaluation ofRadiopharmaceuticals andBiotherapeutics, Health Canada
SUPER EARLYBIRD ENDS
OCTOBER 20TH.HURRY!
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:20 Page 1
“Phacilitate is a must have event on
my calendar”Robert Deans, CTO, BlueRock Therapeutics
“Dynamic,interesting and
highly interactiveevent that promotes
exchange andnetworking in ahighly specialized
field of genetherapy.”
Nathalie Clement, Associate Director, Powell GeneTherapy Center, University of Florida
www.cellandgenetherapyworld.com
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:20 Page 2
WELCOME TO THE WORLD'S LARGEST &MOST INFLUENTIAL MEETING FOR CELL
& GENE THERAPY!
A great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
Steven Goodman, Director, Strategy and Engagement, GSK
PhacilitateLeaders Forum
Miami Phacilitate brings together
industry leaders to explore trends,opportunities, disruptions andmajor shifts on the horizon. Thisyear more than 1,200 decisionmakers and technical experts willunite to collectively shape,experience, and challenge thefuture of advanced therapies.
3 events for the price of 1
The only meeting that connects theENTIRE ecosystem. Our partnershipwith World Stem Cells Summit andco-location with Immuno-OncologyFrontiers World means that you cannow meet biopharma leaders as wellas KOLs from academia, science and
the clinic.
the largestshowcase of
ground-breakingsolutions!
Meet 150+ of the mostinnovative solution and
technology providers who willhelp you to overcome yourbusiness challenges!
“
“
www.cellandgenetherapyworld.com
DECISION MAKERS &
MUCH MORE!
Meet the technical guru's who willhelp streamline and advance yourbusiness processes. Brainstormwith 'super users' and join tailored
training sessions.
Setting a brand new standard fornetworking. From themed cocktailreceptions on the banks of the Miami
Canals, our Japan Partnering Lunch or ouralready-legendary Phacilitate Miami YachtParty, Phacilitate Leaders Forum 2018 willsupport your partnering activities like
never before.
Independent research from AMRInternational scored the event 4.5/5 - join'the world's leading partnering event'
“Rated Excellent”
Stay ahead of the game. Understandsuccessful business and
commercialization models. Identify futuretechnologies and trends. Capitalize on
opportunities!
Meet more decision makers in 4 days than you can in 4months! 1,200+ attendees, 200+ speakers, 100+ exhibitors –meet your next business partners, suppliers, and competitors.
PREMIUM PARTNERING IN THE WINTER SUN
Experience hands-on methods for finding creative solutions tobusiness problems. Take a journey through 4 dedicated
exhibition features - The Bioprocessing Hub, The Supply ChainHub , the Immuno-Oncology Hub and The Translation Academy.
HANDS-ON TECHNOLOGY DEMONSTRATIONS
FUN, EFFECTIVENETWORKING GENUINE MUST ATTEND PRICELESS STRATEGIC &
TACTICAL BUSINESS INSIGHT
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:20 Page 3
JOIN AN INTERNATIONAL COMMUNITY OF INNOVATORS
www.cellandgenetherapyworld.com
Dr Evren Alici, CEO, Vycellix;Director, Cell & Gene Therapy Centre,Karolinska Institutet
Biren Amin, Managing Director &Senior Equity Research Analyst,Biotechnology, Jefferies LLC
Dr Tim Anderson, ManagingDirector, Global PharmaceuticalsEquity Research, Sanford C.Bernstein
Naomi Aronson, PhD, ExecutiveDirector of Clinical Evaluation,Innovation and Policy in the Office ofClinical Affairs,Blue Cross andBlue Shield Association
Dr Mark L. Bagarazzi, CMO,Inovio Pharmaceuticals
Stefano Baila, PhD,Director ofOperations & Business Development,Holding F.I.S.
Jakub Baran, CEO & COO,Famicord Group, Polski BankKomórek Macierzystych S.A.
Shirley Bartido, PhD, MBA,Director, Regulatory Affairs,Cellectis
Dr Nina Bauer, CommercialDevelopment, Autologous Therapies,Lonza, Inc
Dr John Beadle, CEO, PsiOxus
Dr Joanne Bedwell-Garner,Development Director, MacrophagePharma
Kapil Bharti, PhD, StadtmanInvestigator, Unit on Ocular Stem Cell& Translational Research (OSCTR),National Eye Institute, NIH
Diane Blumenthal,Head ofTechnical Operations, SparkTherapeutics
Greg Bonfiglio, Founder &Managing Partner, Proteus, LLC
Dr Christopher Bravery, Director,Advanced Biologicals Ltd
Lee Buckler, President & CEO,RepliCel Life Sciences, Inc
Catherine Cancian, MSc, M.Eng,MBA, Vice President,Pharmaceutical Operations,GenSight Biologics
Dr Stephen Cary, CEO, Omniox
Massimiliano Cesarini, GlobalSales Manager,Comecer Group
Doug Chambers, Head of Viral AndGene Therapy Operations,MilliporeSigma
Kenny Choi, Head of ProcessDevelopment & Tech Transfer,Mustang Bio
Laura Connelly-Smith,MBBCh,DM, Assistant MedicalDirector Apheresis and CellularTherapy, SCCA; Assistant Professor,Division of Hematology,UW;Assistant Member, FHCRC, SeattleCancer Care Alliance
David Courtman, PhD, Director,Biotherapeutics Core Facilities,Ottawa Hospital ResearchInstitute
Sybil Danby, Director of BusinessDevelopment, ParagonBioservices, Inc
Olivier Danos, PhD, Chief ScientificOfficer,REGENXBIO Inc.
Dr Anthony Davies, President,Dark Horse Consulting
Dr John E. Davies, Professor,University of Toronto; President,Tissue RegenerationTherapeutics, Inc
Dr Colleen Delaney, Founder andChief Medical Officer, NohlaTherapeutics
Dr Xavier de Mollerat du Jeu,Director R&D, Life Science Group,Thermo Fisher Scientific
Jerrod Denham, Principal & SeniorConsultant,Dark HorseConsulting, Inc
Boro Dropulic, PhD, MBA, ChiefScientific Officer & General Manager,Lentigen Technology, Inc AMiltenyi Company
Matthew Durdy, Chief BusinessOfficer, Cell and Gene TherapyCatapult
Dr Steve Elliman, CSO,OrbsenTherapeutics, Ltd
Simon Ellison, Cell and GeneTherapy Service Director,WorldCourier
Dr Nicole Faust, Chief ScientificOfficer, CEVEC Pharmaceuticals
Thomas Fellner, Head, CommercialDevelopment, Cell Therapy, LonzaWalkersville
Ed Field, President, brtxDISC™Division,BioRestorativeTherapies
Timothy C. Fong, PhD, MBA, VicePresident, Science & Technology,AllCells
Professor Miguel Forte, ChiefMedical Officer, BoneTherapeutics; Managing Director,mC4Tx (modified Cell forTherapeutics); ChiefCommercialisation Officer and Chairof Commercialisation Committee,ISCT
Marlin Frechette,Director,Regulatory Affairs/Quality Systems,Management Representative, IrvineScientific
Dr Francesco Galimi,GlobalProduct General Manager, EarlyDevelopment, Amgen, Inc
Dr Jason Gersting, Partner,Knobbe Martens
Anna Gilbert,Director, QualityAssurance, Nohla Therapeutics,Inc
Aniz Girach, MD, Chief MedicalOfficer, NightstaRx
Richard Grant, Global VicePresident, Cell Therapy, Invetech
Dr Christine Guenther, CEO &Medical Director, apcethBiopharma GmbH
Jon C. Gunther, PhD, AssociateDirector, Technical R&D, JunoTherapeutics
Heidi M. Hagen, Chief StrategyOfficer,Vineti
Patrick J. Hanley, PhD, LaboratoryFacility Director, Cellular Therapyand Stem Cell Processing, AssistantProfessor of Pediatrics, Children'sNational Health System, TheGeorge Washington University
Brian Hanrahan, Manager, CellTherapy, Invetech
Dorit Harati, Vice President, QualityAssurance, Manufacturing &Logistics,Gamida Cell
Dr Joshua M. Hare,Director,
Interdisciplinary Stem Cell Institute(ISCI), Louis Lemberg Professor ofMedicine,University of MiamiMiller School of Medicine
Dr Don Healey, Senior VicePresident, Operations, KBIBiopharma
Katherine A. High, MD, Presidentand Chief Scientific Officer, SparkTherapeutics
Cade Hildreth, BS, MS, President &CEO,BioInformant.com
Amy Hines, Senior Manager,Apheresis & Collection CenterNetwork Development, Be TheMatch Biotherapies
Dr Bent Jakobsen, CSO,Immunocore
Haiyan Jiang, PhD, Vice President,Preclinical Science, Editas Medicine
Karl K. Johe, PhD, Founder & ChiefScientific Officer,Neuralstem, Inc
Doug Jolly, PhD, Executive VicePresident Research & PharmaceuticalDevelopment, Tocagen, Inc
Louis Juliano, Senior Vice President,Global Sales & BusinessDevelopment,HemaCareCorporation
Dr Bo Kara, Head ProcessDevelopment, Cell & Gene TherapyPlatform CMC, GlaxoSmithKline
Mark A. Kay, MD, PhD, DennisFarrey Family Professor, Departmentsof Pediatrics and Genetics; Vice Chairfor Basic Research (Pediatrics),Stanford University
Avak Kahvejian, PhD, Partner,Flagship Pioneering; Chief InnovationOfficer,Rubius Therapeutics
Dr Hans Keirstead, Chief ExecutiveOfficer,AIVITA BiomedicalCandidate for US Congress
Dr Sven Kili, Vice President & Headof Cell & Gene Therapy Development,Rare Disease Unit,GlaxoSmithKline
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:21 Page 4
www.cellandgenetherapyworld.com
JOIN AN INTERNATIONAL COMMUNITY OF INNOVATORS
David Kirn, MD, co-Founder,Chairman & CEO, 4D MolecularTherapeutics (provisionallyconfirmed)
Dr Karine Kleinhaus, DivisionalVice President, North America,Pluristem Therapeutics
Dr Wolfgang Knirsch, CEO,Vita34 AG
Thomas R. Kreil, PhD, AssociateProfessor of Virology, Head ofPathogen Safety, Shire
Dr Klaus Kühlcke, ManagingDirector, EUFETS GmbH
Dr Joanne Kurtzberg, Director,Carolinas Cord Blood Bank At DukeUniversity; President,Cord BloodAssociation
Dr Brian Lee, President and Co-Founder, PBS Biotech
Alain Lamproye, Chief ExecutiveOfficer,Yposkesi
Benjamin Le Quéré, PhD, BusinessDirector, Bioprocess Solutions, Saint-Gobain
Dr Yijia Li, Director, ShunxiRegenerative Medicine, YunnanProvince Stem Cell Bank
Dr Sheng Lin-Gibson, Leader,Biomaterials Group and Director,Regenerative Medicine Programs,NIST
Dr Ainslie Little,Director ofIntellectual Property,BlueRockTherapeutics
John Lunger, Vice President,Manufacturing & Supply Chain,Adaptimmune
Chris Mason, MD, PhD, CSO,AvroBio
Todd McAllister, PhD, ExecutiveDirector, Amnion Foundation
Dr Michael May, President & CEO,Centre for Commercialization ofRegenerative Medicine (CCRM)
Dr Mark Metzke, Associate,Knobbe Martens
Francois-Thomas Michaud, PhD,CEO, Feldan Therapeutics
Maria T. Millan, MD, InterimPresident & CEO, CaliforniaInstitute for RegenerativeMedicine (CIRM)
Dr Jeffrey Miller, Deputy Directorof the Masonic Cancer Center,University of Minnesota
Timothy J. Miller, PhD, President &CEO,Abeona Therapeutic
stefan Miltenyi, Founder &President, Miltenyi Biotec
Timothy Moore, Executive VicePresident of Technical Operations,Kite Pharma
Dr Shashi Murthy, Professor,Northeastern University
Dr Gopalan Narayanan, VicePresident, Disruptive Biologics,Voisin Consulting Life Sciences(VCLS)
Jessie H.-T. Ni, PhD, Chief ScientificOfficer, Irvine Scientific, JXTGEgroup
Scott Ohanesian, Senior VicePresident of Commercial Operations,Clinical Trial Logistics, QuickSTAT, AQuick Company
Peter Olagunju, Senior Director,Technical Operations, bluebird bio
Dr Biju Parekkadan, AssociateProfessor, Bioengineering, RutgersUniversity; co-Founder, SentienBiotechnologies, Inc
Akshay Peer, PhD, Vice President ofSales & Account Management,TrakCel
Robert Piperno,QA Director, Cell &Gene Therapies,GlaxoSmithKline
Dr Suyash Prasad, Chief MedicalOfficer & Senior Vice President,Audentes Therapeutics
Robert A. Preti, PhD, ChiefExecutive Officer & President, PCT
Dr Joseph Rabinowitz, SeniorDirector of AAV Capsid Development,Bamboo Therapeutics, Inc., awholly owned subsidiary ofPfizer Inc.
Dr Laszlo Radvanyi, Senior VicePresident Head of ImmunoOncologyTranslational Innovation Platform,EMD Serono
Dr Jim Richardson, Deputy Chief,Preclinical Translational Programs,Foundation Fighting Blindness
Dr Anthony Ridgway, ActingDirector, Centre for Evaluation ofRadiopharmaceuticals andBiotherapeutics,Health Canada(provisionally confirmed)
Rodney Rietze, PhD, TechnicalResearch & Development, Cell &Gene Therapy Unit, NovartisPharmaceutical Corporation
Donna Rill, Vice President ofManufacturing, Cell Medica
Dr Isabelle Riviere,Director,Michael G. Harris Cell Therapy & CellEngineering Facility,MemorialSloan Kettering Cancer Center
Dr Greg Russotti, Vice President,Technical Operations,CelgeneCellular Therapeutics
Dr R. Jude Samulski, VicePresident, Gene Therapy, BambooTherapeutics, Inc., a whollyowned subsidiary of Pfizer Inc.
Ziv Sandalon, PhD, AssociateDirector of Innovation & Translation,ABL, Inc.
Ryan Scanlon, Business Head, ViralTherapeutics, Lonza
Dr Joshua Schimmer, SeniorManaging Director, Evercore ISI
Dr Alaina Schlinker, Manager, CellTherapy Application Support,Fresenius Kabi
Albert B. Seymour, PhD, ChiefScientific Officer, HomologyMedicines, Inc
Dr John Sharpe, Chief TechnologyOfficer,Cytonome
Dr Beth Shaz, Chief Medical &Scientific Officer,New York BloodCenter
Elizabeth J. Shpall, MD, Professor,Howard and Lee Smith Chair inCancer Research; Director, CellTherapy Laboratory and Cord BloodBank; Deputy-Chair, DepartmentStem Cell Transplantation andCellular Therapy,University ofTexas MD Anderson CancerCenter
Dr Euan Slorach, Senior Scientist,Caribou Biosciences
Dr Alan K. Smith, Executive VicePresident, Technical Operations,Bellicum Pharmaceuticals
Robert Smith, Senior Vice Presidentand Early Commercial Lead, GeneTherapy Research Unit, Pfizer, Inc
Richard O. Snyder, PhD, ChiefScientific Officer, Brammer Bio
Rizwana F. Sproule, PhD, VicePresident, Regulatory Affairs,KitePharma, Inc
Dr David F. Stroncek, Chief, CellProcessing Section, Department ofTransfusion Medicine, NIH ClinicalCenter
Nicolas Theys, PhD, ChiefOperating Officer, NovadipBiosciences
Dr Jan Thirkettle, ChiefDevelopment Officer, FreelineTherapeutics
Dr Mark Throsby, CSO,Merus
Dr Pascal Touchon, Senior VicePresident, Global Head StrategyBD&L; Executive Board Member,Novartis Oncology
Luk H. Vandenberghe, PhD,Director, Grousbeck Gene TherapyCenter, Mass Eye and Ear, AssistantProfessor,Harvard Medical School
Dr David Venables, CEO,Synpromics
Frances Verter, PhD, Founder &Director, Parent's Guide to CordBlood Foundation &CellTrials.org
Adam Villa, Director, ClinicalProduct Logistics, CRISPRTherapeutics
Deborah Wild, Vice President ofQuality & Regulatory Affairs,Paragon Bioservices, Inc
Mark Zimmerman, PhD, VicePresident, Strategy and BusinessDevelopment, Interim Vice Presidentof Operations, ViaCyte
Sanjin Zvonic, PhD, Senior Director,Business Leader, Clinical &Commercial Manufacturing, PCT
Claudia Zylberberg, PhD, CEO,Akron Biotech
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:21 Page 5
PARTNERING TABLES
TRANSLATION ACADEMY WITH CCRM
IO HUB
724718
617615
716710
611609
706704 702
700
601603605
708
707 705 703 711
618616
614
519517
515
610
511
501
411
508
409
504502
401403
405
418416
414
319317
315
410408
311309
406
305
303
318316
314
219
217215
210308
211209
109
206
107
815814
715717
722720
714712
808
709
THE BIOPROCESS HUB
PHACILITATE SALES OFFICE
www.cellandgenetherapyworld.com
EXPERIENCE THE WORLD'S LARGEST SHOWCASE OF CELL & GENE THERAPY PIONEERS
206 Brooks Life Science
209 BioLife Solutions
210 Akron Biotech
211 Comprehensive CellSolutions
215 Wilson Wolf
303 Paragon Bioservices
305 Saint-Gobain Life Sciences
308 Key Biologics
309 MedCision
311 Eufets
314 The Cell and Gene TherapyCatapult
315 World Courier
319 Waisman Biomanufacturing
401 Sony Biotechnology
403 Quick· SpecializedHealthcare Logistics
405 Cobra Biologics
406 PCI Clinical Services
408 Fresenius Kabi
409 CellGenix
410 Lonza Biologics
411 PCT
414 TrakCel
416 G-CON Manufacturing
418 Sartorius Stedim
501 Thermo Fisher Scientific
502 KBI BioPharma
504 GE Healthcare
508 Irvine Scientific
511 Brammer Bio
515 Miltenyi Biotec
517 Diamond Pharma Services
519 ABL
601 PendoTECH
603 WuXi AppTec
605 Biocair
609 PeproTech
610 PBS Biotech
611 Bio-Techne
614 Vineti
615 ChemoMetec A/S
616 BioSpherix
617 Yposkesi
618 Terumo BCT
700 Be The MatchBioTherapies®
702 Hamilton Storage
706 Aldevron
707 CEVEC PharmaceuticalsGmbH
709 Myriad RBM
710 MAK-SYSTEM
711 Corning Inc
712 OmniSeq
714 VGXI Inc
715 Becton Dickinson
716 Blood Centers of America
718 Comecer S.p.A
720 MaxCyte
The Translation Academy: In partnering with CCRM, explore
industry-academic convergence, learnabout promising innovation andunderstand the pathways to
commercialsuccess, focusing on thethemes of:• Financing
• Manufacturing• Regulatory
• Reimbursement
The Supply Chain Hub: A vein-to-vein experiential journey throughpatient registration to transit, storage and
point of care administration
The I-O Hub:Gain expert insights from solution providersand technology pioneers who are key to the
progress of pre-clinical and clinicaldevelopment in I-O.
The Bioprocess Hub:Everything that you need to know aboutthe cutting edge solutions availableacross harvesting, cell expansion,purification, sorting and QA/QC
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:21 Page 6
Full Day Comparability Workshop
Christopher Bravery9:00 – 17:00, Monday 22 January
$895Change is inevitable and necessary both in development and overthe post-approval product lifecycle. Whenever changes are made itis necessary to confirm they do not adversely impact the quality andtherefore safety and efficacy of the product; this requires databeyond meeting current specifications. With any biological productthis is challenging, for cell, gene and tissue products that cannot befully characterised the challenges are greater still. Concerns aboutcomparability undertaken during development are common issues atapproval with significant comparability concerns raised during 12 ofthe 17 ATMP submissions to the EMA. Such questions often delaymarket approval or contribute to failure to get approval. This courseexplains what comparability is and how to develop a successfulcomparability protocol.
Workshop Learning Overview:• What is comparability?• Why is meeting existing specifications not comparability?• How do I apply the principles of comparability to highly variableproducts?
• Case studies: Common mistakes with comparability and theirconsequences.
• Interactive exercise: Spot the weaknesses and proposeimprovements to a worked comparability study
Half Day Quality-by-Design
Anthony Davies & Jerrod Denham9:00 – 12:30, Monday 22 January
$495Quality by Design (QbD) is a science- and risk-based approach topharmaceutical development. Applied to manufacturing processes, itis intended to ensure a rational and cost-effective approach toproduct quality. Both the EMA and FDA have systematicallyassessedQbD elements of regulatory filings and, especially since theFDA’s 2011 Process ValidationGuidance and the ICH’s Q8 through Q11, it has become an intrinsicpart of regulatory guidance.
However, understanding and adoption of the principles of QbD hasremained relatively limited in the field of cell and gene therapy. Westrongly believe that its methodologies are critical to the successfuldevelopment of ATMPs and that they should be incorporated asearly as possible into the science of manufacturing. This workshopwill both demystify the fundamentals of QbD and provide concreteexamples of its application to this field. You will leave with a crystal-clear understanding of P Diagrams, RAMM matrices, the QTPP andmany more tools which you can immediately use to improve yourproducts and processes.
Half Day Intellectual Property 101
Mark Metzke & Jason Gersting13:30 – 17:00, Monday 22 January
$495This session is geared towards providing an overview of intellectualproperty, including trademarks, design patents and utility patents,geared especially for those new to the process. The course willinclude a general overview of different types of IP that a companymay employ to develop a robust portfolio to build and protect theirbrand, as well as their contemplated commercial products. Thesession will emphasize utility patents (their specifications andclaims), different types of applications (provisionals, non-provisionals, continuations, divisionals, and continuations-in-part),and what patents do and do not allow patentees to do (enforcementversus the ability to practice patents). The session will cover the nutsand bolts of the patenting process from conception of an invention,to filing/claiming strategies, to prosecution, patenting, andconsiderations for continued filings, with an aim to touch ondomestic and international strategies at a high level. Timepermitting, an interactive session will be held where filing strategiesare developed for hypothetical inventive entities.
Key Benefits:• High level overview of different types of IP• Distilled overview of utility patents and the patenting process• Overview of patent application types including considerations onwhen to file
• Interactive session to reinforce the course
Half Day Authoring the Common Technical Document
Christopher Bravery11:15 – 15:30, Thursday 25 January
$495The ICH Common Technical Document was developed tostandardize the way information is shared with regulators, and isaccepted or mandatory by agencies following ICH (e.g. EU, US,Japan, Canada etc). The CTD is used for all types of medicinalproduct but the purpose of each section may not always be clear forATMP. This workshop aims to clarify:• What the purpose of each section is• Whether the section is descriptive or data-driven• What sorts of data are expected• Tips and considerations for style, use of figures and tables, etc.
Pricing Explained
Each course is available to book separately, or booktwo half day courses for $895 and save $95! Simply register for your conference pass and add yourchoice of courses to your basket.
www.cellandgenetherapyworld.com
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:21 Page 7
Meet the Trainers
Dr Anthony Davies, President, Dark Horse ConsultingAfter training as a biochemist, chemical engineerand molecular biologist, Anthony Davies hasworked in the cell and gene therapy field for some20 years. Anthony is now Executive Chairman ofDark Horse Consulting, a boutique consultingpractice which he founded in 2014, where hefocuses on strategic CMC and productdevelopment issues in cell and gene therapy.
www.cellandgenetherapyworld.com
Christopher Bravery,Director, Advanced Biologicals LtdChristopher founded Consulting on AdvancedBiologicals Ltd at the end of 2009 in order to focushis activities within the Regenerative Medicinesector. Christopher has spent most of his careerworking in regenerative medicine; starting with aPhD in xenotranplantation immunology. Christopherwas involved with national implementation of thenew Advanced Therapies Regulation and alsoinvolved through his participation in the CHMP’s cellproducts working party (CPWP) in implementationat the EMA level including drafting guidelines.
Jerrod Denham, Principal & SeniorConsultant, Dark Horse Consulting, IncAfter training at UCLA in Molecular Biology andPhysiological Sciences, Jerrod Denham hasworked in the cell therapy industry for 18 yearswith increasing roles of responsibility. Jerrod isnow a Principal and Senior Consultant at DarkHorse Consulting, where he focuses on upstreamand downstream process engineering for cell andgene therapy products.
Mark Metzke, Associate, Knobbe MartensMark A. Metzke has been an intellectual propertyattorney at Knobbe Martens since 2011. He has aclient practice with a focus on patent prosecutionand strategic portfolio management in thepharmaceutical and biotechnological fields. Markearned his Ph.D. from at the University ofCalifornia, Irvine, researching synthetic genedelivery vectors and biomaterials. He earned hisJ.D. from UCLA Law, where he focused onintellectual property law and was the Editor-in-Chief of the Journal of Law and Technology.
Jason Gersting, Partner, Knobbe MartensJason Gersting is a partner in the Orange Countyoffice. He focuses on patent and trademarkprosecution and strategic intellectual propertyportfolio management in the biotechnology andlife science industries. Dr. Gersting earned hisPh.D. and J.D. from the University of Florida,where his research focused on role of fetalneuroendocrine signaling and prostaglandins inthe initiation of labor and delivery at theconclusion of pregnancy. He also earned hismaster’s degree by developing methods to analyzedifferential expression of calcium channels inresponse to disease or injury.
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:21 Page 8
AGENDA
7.30 Registration & Buffet Breakfast in the Exhibition Area
9.00 Chair’s introductionChris Mason, MD, PhD, CSO,AvroBio
9.05 2017’s Top 10 Events: Celebrating recent progress in the field whilst putting it into contextEd Field, President, brtxDISC™ Division, BioRestorative Therapies
9.20 Keynote Address - Reviewing the development stories and market access plans for 2017’s most high-profile product candidates Katherine A. High, MD, President and Chief Scientific Officer, Spark Therapeutics
9.40 Practical HTA and market access insights and solutions for current and future approved cell & gene therapy products Panellists:Naomi Aronson, PhD, Executive Director of Clinical Evaluation, Innovation and Policy in the Office of Clinical Affairs, Blue Cross and Blue Shield AssociationDr Sven Kili, Vice President & Head of Cell & Gene Therapy Development, Rare Disease Unit, GlaxoSmithKlineDr Jim Richardson,Deputy Chief, Preclinical Translational Programs, Foundation Fighting Blindness
10.30 How to drive the cost-effective execution of cell & gene therapy commercialization at the operational level? Moderator:Matthew Durdy, Chief Business Officer,Cell and Gene Therapy CatapultPanellists: Rodney Rietze, PhD, Technical Research & Development, Cell & Gene Therapy Unit,Novartis Pharmaceutical CorporationRichard Grant,Global Vice President,Cell Therapy, Invetech
11.00 Morning Coffee in the Exhibition Area
Opening plenary session
2017: The Year Everything Changed
www.cellandgenetherapyworld.com
DAY 1: TUESDAY, JANUARY 23
4.30 Registration for Phacilitate Cell & Gene Therapy World 2018 opens
6.00 Plenary Super SessionChanging modern medicine (Shared with I-O Frontiers 2018)Chair: Dr Anthony Davies, President,Dark Horse Consulting
A series of Fireside Chats with:Dr Pascal Touchon, Senior Vice President, Global Head Strategy BD&L; Executive Board Member,Novartis OncologyDr Tim Anderson, Managing Director, Global Pharmaceuticals Equity Research, Sanford C. BernsteinDr Hans Keirstead, Chief Executive Officer, AIVITA BiomedicalCandidate for US CongressStefan Miltenyi, Founder & President,Miltenyi Biotec
7.30 Gala Welcome Drinks Reception on The Terrace
Sponsored by
For full conference agenda www.cellandgenetherapyworld.com/agenda
PRE-CONFERENCE DAY:MONDAY, JANUARY 22
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:22 Page 9
AGENDA
www.cellandgenetherapyworld.com
4 parallel breakout tracks for the rest of the day:
Defining best practices forCost of Goods control
Cell-based Therapy Track
Gene Therapy Track
Evaluating I-O Responders vs non-responders: Paving the way to higher
patient response rates
Emerging Science Track: O
ncology
Supply Chain Track see page 17
11.30Bioprocess R&D, scale up/out,commercial facility planning andregulatory lessons learned by celltherapy industry leaders• Bioprocess automation – identifying
current and future key priority areas fortechnology development
• Bioprocess acceleration (eg. of celltransduction) – where can one feasibly savetime, therefore reducing cost and risk,currently?
• Creating bioprocess-related efficienciesaround quantities of consumables andmaterials required
Chair: Professor Miguel Forte, ChiefMedical Officer, Bone Therapeutics;Managing Director,mC4Tx (modified Cellfor Therapeutics); Chief CommercialisationOfficer and Chair of CommercialisationCommittee, ISCTSpeakers: Rodney Rietze, PhD, Technical Research& Development, Cell & Gene Therapy Unit,Novartis Pharmaceutical CorporationTimothy Moore, Executive Vice Presidentof Technical Operations,Kite PharmaHeidi M. Hagen, Chief Strategy Officer,VinetiDr Brian Lee, President and Co-Founder,PBS BiotechBenjamin Le Quéré, PhD, BusinessDirector, Bioprocess Solutions, Saint-Gobain
How to address questions and challengesaround gene expression longevity/control,
immunogenicity and re-dosing in in vivo gene therapy?
11.30Comparing and contrasting differentAAV serotypes and novel capsidmodification-based approaches • Is immunogenicity a real problem?• How are recent breakthroughs ingene expression monitoring enablingthe space?
• How are the sector’s R&D leadersapproaching the re-administrationconundrum?
• What to the FDA would a morestandardized scenario look like forAAV gene therapy clinical application?
Chair: Dr Gopalan Narayanan, VicePresident, Disruptive Biologics, VoisinConsulting Life Sciences (VCLS)Speakers: Dr R. Jude Samulski, Vice President, GeneTherapy, Bamboo Therapeutics, Inc., awholly owned subsidiary of Pfizer Inc.Olivier Danos, PhD, Chief ScientificOfficer,REGENXBIO Inc.Luk H. Vandenberghe, PhD, Director,Grousbeck Gene Therapy Center, Mass Eyeand Ear, Assistant Professor, HarvardMedical SchoolAniz Girach, MD, Chief Medical Officer,NightstaRxDavid Kirn, MD, co-Founder, Chairman &CEO, 4D Molecular Therapeutics(provisionally confirmed)Dr David Venables, CEO, Synpromics
11.30Chairs Introduction
11.35Predictive Biomarkers in CancerImmunotherapyJeff Evelhoch, VP, Head of TranslationalBiomarkers,Merck ResearchLaboratories
11.50An Immune Report Card to Enrich forImmunotherapy Clinical TrialsMark Gardner, CEO,OmniSeq, Inc
12.05MRI tools for detection of clinical celltherapy products post-transferProfessor Eric Ahrens, Professor ofRadiology,University of California SanDiego
12.25Panel: How do we better understandresponse patterns to identify andmonitor clinical end points in immuno-oncology? Panellists: Speakers of the session
For full conference agenda www.cellandgenetherapyworld.com/agenda
13.00Close of session - Buffet Lunch in the Exhibition Area
OR
Lunch Workshop Sponsored byThe Influence of the Apheresis Product on CAR T-cell ManufacturingSpeaker: Laura Connelly-Smith, MBBCh,DM, Assistant Medical Director Apheresis and Cellular Therapy, SCCA; Assistant Professor, Division of Hematology, UW; Assistant Member, FHCRC, Seattle Cancer Care Alliance
OR
Roundtable discussion -Discussion of the major AAV manufacturing platforms
(Highly interactive small group discussion for a maximum of 12 participants)Moderator: Sybil Danby, Director of Business Development, Paragon Bioservices, Inc
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:22 Page 10
AGENDA
www.cellandgenetherapyworld.com
Securing sufficient manufacturingcapacity for a commercializing sector –what are the most viable short- and long-
term solutions?Part 1 - Outsourcing
Cell-based Therapy Track
Gene Therapy Track
Back to Basics: The road map torationalising combination trial designs for
clinical success
Emerging Science Track: O
ncology
Supply Chain Track see page 17
14.00How are CMO consolidation trends andbusiness/ collaboration models set toevolve (eg. the ‘one-stop shop’)? • What will be the impact for cell &gene therapy developers? On Cost ofGoods?
• When is/isn’t the right time toapproach a CMO?
Sanjin Zvonic, PhD, Senior Director,Business Leader, Clinical & CommercialManufacturing, PCTMatthew Durdy, Chief Business Officer,Cell and Gene Therapy CatapultThomas Fellner,Head, CommercialDevelopment, Cell Therapy, LonzaWalkersvilleDr Alan K. Smith, Executive VicePresident, Technical Operations, BellicumPharmaceuticals
Non-viral vectors: What are the pros andcons in clinical application compared to viral
platforms?
14.00What are the advantages/disadvantagesand common issues with the variousplatforms? (Eg. RNA, plasmid DNA,Sleeping Beauty) • What technologies can potentially be‘re-purposed’ for non-viral genetherapy applications?
Mark A. Kay, MD, PhD, Dennis FarreyFamily Professor, Departments of Pediatricsand Genetics; Vice Chair for Basic Research(Pediatrics), Stanford UniversityDr Mark L. Bagarazzi, CMO, InovioPharmaceuticalsFrancois-Thomas Michaud, PhD, CEO,Feldan Therapeutics
14.05Chairs Introduction
14.05Rational Combinations in anIr-Rational WorldAiman Shalabi, Chief Medical Officer,Venture Fund, Clinical Accelerator,CancerResearch Institute
14.20Addressing the Tidal Wave of CancerImmunotherapy Combinations ThroughInnovative Trial DesignsDr William Grossman, GlobalDevelopment Team Leader Tecentriq - GI &Cancer Immunotherapy Combinations -SolidTumors,Genentech
14.35Presentation reserved
14.50Debate: Rational Trial Design vsEmpirical Science• Which application provides mostcommercial benefit in the eyes ofindustry and regulators?
Speakers include:Dr William Grossman, GlobalDevelopment Team Leader Tecentriq - GI &Cancer Immunotherapy Combinations -SolidTumors,GenentechDr Roy Baynes, SVP & Head GlobalClinical Development, Chief Medical Officer,Merck Research Laboratories
15.30Afternoon Tea in the Exhibition Area
OR
Technology Showcase sponsored by Jessie H.-T. Ni, PhD, Chief Scientific Officer, Irvine Scientific, JXTGE group
Securing sufficient manufacturing capacityfor a commercializing sector – what are themost viable short- and long-term solutions?
Part 2 - In-house
Cell-based Therapy Track
Gene Therapy Track
Engaging with precision medicine: Adoptingthe use of immuneprofiling andbioinformatics to enhance
clinical development
Emerging Science Track: O
ncology
Supply Chain Track see page 17
16.00Just how realistic an option is ‘do ityourself’ bioprocessing for cell & genetherapy developers today? • To what extent have recenttechnological innovations (eg. closed,disposable bioprocessing solutions)opened the door to in-housemanufacture?
Gene editing platforms in therapeuticapplication
16.00What do we know so far about theefficiency/accuracy/safety of the variousgene editing platforms in both in vivoand ex vivo therapeutic applications? • How to remodel the existingpreclinical paradigm to enable thedevelopment of gene editingmedicine?
• Comparing the clinical trial protocolsof trailblazers
16.00Chairs IntroductionDr Masahide Yano, Research Scientist,Center for Drug Evaluation & Research,FDA (Provisionally confirmed)
16.05Genomics- a Silver BulletDr William Loging, Head, ProductionBioinformatics, Genetics & GenomicsSciences, Icahn School of Medicine,Mount Sinai
For full conference agenda www.cellandgenetherapyworld.com/agenda
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:22 Page 11
AGENDA
www.cellandgenetherapyworld.com
Securing sufficient manufacturing capacityfor a commercializing sector – what are themost viable short- and long-term solutions?
Part 2 - In-house
Cell-based Therapy Track
Gene Therapy Track
Engaging with precision medicine: Adoptingthe use of immuneprofiling andbioinformatics to enhance
clinical development
Emerging Science Track: O
ncology
Supply Chain Track see page 17
• How to address the key remaininglimitations (eg. scalability, ‘open’ inter-unit operation transitions andsampling, etc)?
• How do we link in-housemanufacturing sites?
Jon C. Gunther, PhD, Associate Director,Technical R&D, Juno TherapeuticsDorit Harati, Vice President, QualityAssurance, Manufacturing & Logistics,Gamida CellKenny Choi,Head of Process Development& Tech Transfer, Mustang BioMassimiliano Cesarini,Global SalesManager,Comecer Group
Gene editing platforms in therapeuticapplication
• How do we match genome editingtechnologies with viral and non-viralvector delivery platforms?
Albert B. Seymour, PhD, Chief ScientificOfficer, Homology Medicines, IncHaiyan Jiang, PhD, Vice President,Preclinical Science, Editas Medicine
16.20Presentation Dr Steven Anderson, Chief ScientificOfficer, Covance; Senior Vice President,Laboratory Corporation of America
16.35PresentationDr Scott Bornheimer, Applied researchmanager,BD Biosciences
16.50A Platform for the Discovery andValidation of Immune Gene ExpressionSignatures to Enhance CancerImmunotherapyDr. James J. Mulé, Associate CenterDirector, Translational Research, Director ofCell-Based Immunotherapies, MoffittCancer Center
17.05Panel: Transforming datasets intoactionable informationPanellists: speakers of the session
17.30Close of Day 1 – Drinks Reception in the Exhibition Area
DAY 2:WEDNESDAY, JANUARY 24
7.15Registration & Buffet Breakfast in the Exhibition Area
OR
7.30Breakfast Briefing sponsored byChallenges of cell therapy automation: a perspective on disposablesBenjamin Le Quéré, PhD, Business Director, Bioprocess Solutions, Saint-Gobain
OR
Breakfast Briefing sponsored by Exploring the value of proprietary platforms in progressing your therapyFacilitator: Brian Hanrahan, Manager, Cell Therapy, InvetechPanellists include:Rodney Rietze, PhD, Technical Research & Development, Cell & Gene Therapy Unit, Novartis Pharmaceutical CorporationTimothy Moore, Executive Vice President of Technical Operations, Kite PharmaKim Warren, PhD, Head of Operations, AvroBio Inc.
For full conference agenda www.cellandgenetherapyworld.com/agenda
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:22 Page 12
AGENDA
Followed by your choice of 5 parallel breakout tracks:
8.45 Chair’s introduction
8.50 Investor Keynote Panel: tips for successfully navigating today’s uncertain financing environmentPanellists:Biren Amin, Managing Director & Senior Equity Research Analyst, Biotechnology, Jefferies LLCDr Joshua Schimmer, Senior Managing Director, Evercore ISIGreg Bonfiglio, Founder & Managing Partner, Proteus, LLCDr Jim Richardson, Deputy Chief, Preclinical Translational Programs, Foundation Fighting Blindness
9.40 2017: the year of the partnership! How diverse key cell & gene therapy’s stakeholders are pulling together to build the foundations for a bright commercial futureSpeakers/panellists:Robert Smith, Senior Vice President and Early Commercial Lead, Gene Therapy Research Unit, Pfizer, IncMaria T. Millan, MD, Interim President & CEO, California Institute for Regenerative Medicine (CIRM)Dr Sheng Lin-Gibson, Leader, Biomaterials Group and Director, Regenerative Medicine Programs, NIST
10.45 Morning Coffee in the Exhibition Area
Morning Plenary Session
Macro economic insights and innovative collaboration models to drive cell & gene therapy’s ongoing maturation
Tour of the Bioprocess Hub
Cell-based Therapy Track
Gene Therapy Track
Cardiomyocytes, pancreatic islet cells,MSCs… do the latest data support the
recent revival in regenerative medicine? Emerging Science Track: O
ncology
Supply Chain Track see page 17
11.15This session will be staged in our brandnew Bioanalytics Hub in the exhibitionarea – an experiential journey to thecutting edge in comparability, potency,stability, sterility and purity testin
OR, running concurrently:
Panel: What is the desired future statefor contract manufacturing for celltherapy?• Lessons from CMOs in mature fieldsModerator: Sanjin Zvonic, PhD, SeniorDirector, Business Leader, Clinical &Commercial Manufacturing, PCT
How to address viral and non-viralvector manufacturing capacity/supplyshortfalls before they reach crisis point?
11.15Defining both the scale of thechallenge and the strategic solutionsavailable today and in the near future…for AAV…for lentiviral…for retroviral…for plasmid DNA• In-house or outsource? Weighing upthe key considerations of each whenseeking to guarantee sufficient/scalable and secure vector supply
• What will the optimal vectormanufacturing facility of the futurelook like?
Chair: Boro Dropulic, PhD, MBA, ChiefScientific Officer & General Manager,Lentigen Technology, Inc A MiltenyiCompanyRyan Scanlon, Business Head, ViralTherapeutics, LonzaDr Nicole Faust, Chief Scientific Officer,CEVEC PharmaceuticalsDr Klaus Kühlcke,Managing Director,EUFETS GmbH Ziv Sandalon, PhD, Associate Director ofInnovation & Translation,ABL, Inc.Dr Joseph Rabinowitz, Senior Directorof AAV Capsid Development,BambooTherapeutics, Inc., a wholly ownedsubsidiary of Pfizer Inc.Dr Xavier de Mollerat du Jeu, DirectorR&D, Life Science Group, Thermo FisherScientific
11.15Case studies & audience Q&A• Are we finally getting to the bottomof theunpredictability/inconsistency inefficacy data from clinicalapplication?
• What progress in betterunderstanding Mechanisms ofAction?
• How to build more efficacy/potencyinto the product profile?
Dr Joshua M. Hare, Director,Interdisciplinary Stem Cell Institute (ISCI),Louis Lemberg Professor of Medicine,University of Miami Miller School ofMedicineNicolas Theys, PhD, Chief OperatingOfficer, Novadip BiosciencesDr Biju Parekkadan, AssociateProfessor, Bioengineering, RutgersUniversity; co-Founder, SentienBiotechnologies, Inc
Cell-based therapy track : Tour of the Bioprocess Hub: An experiential journey which highlights the cutting edge solutions available across harvesting, cell expansion, purification, sorting and QA/QC
www.cellandgenetherapyworld.com
Cord Blood & Perinatal Stem Cells Track see page 16
13.00Buffet Lunch in the Exhibition Area
OR
Workshop sponsored by
OR
Japan Partnering Lunch
For full conference agenda www.cellandgenetherapyworld.com/agenda
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:23 Page 13
AGENDA
www.cellandgenetherapyworld.com
Supply Chain Track: Tour of the Supply Chain Hub:A vein-to-vein experiential journey through patient registration to transit, storage and point of care administration
How to rationalize QCfor commercial scale?
Cell-based Therapy Track
Gene Therapy Track
Genetically modified stem cells – hope or hype?
Emerging Science Track: O
ncology
Supply Chain Track see page 17
14.00Where can improvements be made atthe strategic level to the three keyelements: cost, speed andreproducibility of results? • What are the learnings we can takeas a sector from recent BLA filings interms of expectations andrequirements around quality,process controls, etc?
• What to do about extractables andleachables?
• How to accelerate release testingwithout compromising onrobustness?
• Driving regulatory guideline andstandards development
Dr Greg Russotti, Vice President,Technical Operations,Celgene CellularTherapeuticsStefano Baila, PhD, Director ofOperations & Business Development,Holding F.I.S.Dr Sheng Lin-Gibson, Leader,Biomaterials Group and Director,Regenerative Medicine Programs, NISTAnna Gilbert, Director, QualityAssurance,Nohla Therapeutics, IncShirley Bartido, PhD, MBA, Director,Regulatory Affairs, CellectisDr Christine Guenther, CEO & MedicalDirector, apceth Biopharma GmbH Doug Chambers, Head of Viral And GeneTherapy Operations,MilliporeSigma
Highlighting and addressing ‘critical path’issues in bringing vector manufacturingprocesses from Phase I/II to commercial
scale
14.00Maturation of processes, analytics, andspecifications as the manufacture ofvector products progresses towardslate stage clinical trials and commerciallaunch • Process characterization andscalability strategies
• Process control and validationstrategies
• Assay qualification and validationstrategies
• Vector product profiles andspecifications
Chair:Richard O. Snyder, PhD, Chief ScientificOfficer,Brammer BioSpeaker:Diane Blumenthal,Head of TechnicalOperations, Spark TherapeuticsDr Jan Thirkettle, Chief DevelopmentOfficer, Freeline Therapeutics Catherine Cancian, MSc, M.Eng, MBA,Vice President, PharmaceuticalOperations, GenSight BiologicsDoug Jolly, PhD, Executive VicePresident Research & PharmaceuticalDevelopment, Tocagen, Inc
14.00Do the latest preclinical and clinicaldata suggest an answer to the efficacyconundrum is within reach?• Has the time come for iPS celltherapies? (How to address theremaining issues? What are the leastrisky potential applications?)
• HSCs• MSCsKapil Bharti, PhD, StadtmanInvestigator, Unit on Ocular Stem cell &Translational Research (OSCTR),National Eye Institute, NIH Avak Kahvejian, PhD, Partner, FlagshipPioneering; Chief Innovation Officer,Rubius TherapeuticsDr Christine Guenther, CEO & MedicalDirector, apceth Biopharma GmbH
Cord Blood & Perinatal Stem Cells Track see page 16
For full conference agenda www.cellandgenetherapyworld.com/agenda
15.30Afternoon Tea in the Exhibition Area
Sense-checking product characterizationassay development – which tools
do we really need?
Cell-based Therapy Track
Gene Therapy Track
Tracking the migration of regenerativemedicine to new therapeutic areas and
indications
Emerging Science Track: O
ncology
Supply Chain Track see page 17
16.00Optimizing current assays and next-generation bioanalytics: what are thekey changes needed to legacypharmaceutical/biological qualitysystems currently employed in the celltherapy space? • Potency – what are the best assaysfor cell therapy? How relevant ispotency to clinical efficacy?
• What are the latest technologicaladvances (in the sensor field, forinstance)? And what are the criticaltechnologies or assays still missingfrom the toolbox?
• Defining next steps in drivingautomation: which assays should webring in-process? And how will weintegrate in-process and externalassays?
Comparing and contrasting current andemerging gene therapy productionplatforms and characterization tools
16.00• Which platform(s) will provide thefuture gold standard for robust,reproducible and cost effectiveproduction of viral vectors fromproducercell lines?
• Gene therapy productcharacterization and potency testing
Timothy J. Miller, PhD, President &CEO, Abeona TherapeuticsAlain Lamproye, Chief Executive Officer,YposkesiDr Joseph Rabinowitz, Senior Directorof AAV Capsid Development, BambooTherapeutics, Inc., a wholly ownedsubsidiary of Pfizer Inc.Deborah Wild, Vice President of Quality& Regulatory Affairs, ParagonBioservices, Inc
16.00Case studies & audience Q&A• What is the clinical justification todate for hopes pinned to diabetes andCNS applications, for instance?
• Exploring new frontiers in aestheticmedicine
Mark Zimmerman, PhD, Vice President,Strategy and Business Development,Interim Vice President of Operations,ViaCyteDavid Courtman, PhD, Director,Biotherapeutics Core Facilities,OttawaHospital Research InstituteKarl K. Johe, PhD, Founder & ChiefScientific Officer, Neuralstem, IncLee Buckler, President & CEO,RepliCelLife Sciences, Inc
Cord Blood & Perinatal Stem Cells Track see page 16
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:23 Page 14
AGENDA
www.cellandgenetherapyworld.com
17.30Yacht Party
DAY 3: THURSDAY, JANUARY 25
7.30 Registration & Buffet Breakfast in the Exhibition Area
Morning Plenary Session
Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector
For full conference agenda www.cellandgenetherapyworld.com/agenda
Sense-checking product characterizationassay development – which tools
do we really need?
Cell-based Therapy Track
Gene Therapy Track
Tracking the migration of regenerativemedicine to new therapeutic areas and
indications
Emerging Science Track: O
ncology
Supply Chain Track see page 17
Chair:Dr Christopher Bravery, Director,Advanced Biologicals LtdDr David F. Stroncek, Chief, CellProcessing Section, Department ofTransfusion Medicine,NIH ClinicalCenterSpeakers:Patrick J. Hanley, PhD, LaboratoryFacility Director, Cellular Therapy and StemCell Processing, Assistant Professor ofPediatrics, Children's National HealthSystem, The George WashingtonUniversityJon C. Gunther, PhD, Associate Director,Technical R&D, Juno TherapeuticsDr Shashi Murthy, Professor,Northeastern UniversitySpeaker from WuXi AppTec TBA
Comparing and contrasting current andemerging gene therapy productionplatforms and characterization tools
Cord Blood & Perinatal Stem Cells Track see page 16
9.00 Chair’s introduction
Reviewing the pivotal trial design/regulatory review stories of 2017’s most high-profile product candidates in pivotal trials – what are the key regulatory insights andprecedents for the cell & gene therapy sector to take forward? (Eg, in terms of successfully navigating the Breakthrough Designation route to market approval?) Speakers to include:Rizwana F. Sproule, PhD, Vice President, Regulatory Affairs, Kite Pharma, Inc
9.40 21st Century Cures and the RMAT Designation, one year on - regulator and early user experiences: how has it been implemented?FDA Speaker TBA
10.15 Comparing and contrasting expedited development and conditional approval pathways, both within the US and worldwide Speakers to include:Dr Anthony Ridgway, Acting Director, Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics, Health Canada(provisionally confirmed)
10.45 Morning Coffee in the Exhibition Area
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:23 Page 15
AGENDA
www.cellandgenetherapyworld.com
For full conference agenda www.cellandgenetherapyworld.com/agenda
Cell-based Therapy Track
Emerging Science Track
How to truly enable decentralized manufacturing at commercialscale?
Pointing the way to future R&D success in rare indications
3 parallel breakout tracks:
11.15How comfortable are industry, regulators, clinicians andhealthcare providers alike with moving cell & gene therapybioprocessing closer to patients? Where do their chief remainingconcerns lie? • What would increasing point of care manufacturing mean forGMP oversight/levels, moving forward?
• How to (re-)design workflows around raw material acquisition,logistics and quality/release testing in the decentralizedscenario?
• How to deal with the thorny issue of demonstratingcomparability across multiple clinical sites?
• How far away is the fully sealed, ‘GMP in a box’ bedside solutionin reality?
Dr Bo Kara, Head Process Development, Cell & Gene TherapyPlatform CMC,GlaxoSmithKlinePeter Olagunju, Senior Director, Technical Operations, bluebirdbioDr Nina Bauer, Commercial Development, Autologous Therapies,Lonza, Inc
11.15Case studies• Preclinical strategy: critical insights for effective, rapidtranslation to First in Man
• Clinical trial design insights and data updates from globalleaders in AAV and non-viral vector-driven in vivo gene therapy
• How running Natural History of Disease studies isrevolutionising clinical trial designs in rare diseases
• Rare diseases: value of surrogate endpoints in clinical trials• Progress with targeted delivery and vector engineering: is thein vivo gene therapy field now ready to tackle ‘non-traditional’targets (eg . in the CNS space)?
Dr Suyash Prasad, Chief Medical Officer & Senior Vice President,Audentes TherapeuticsAniz Girach, MD, Chief Medical Officer,NightstaRxTimothy J. Miller, PhD, President & CEO,Abeona Therapeutics
13.00Buffet Lunch in the Exhibition Area
OR in the Translation Academy
Cell & Gene Therapy World in summary: Highlights and trends from this year’s eventSpeaker: Robert A. Preti, PhD, Chief Executive Officer & President, PCT
Cell-based Therapy Track
Emerging Science Track
How to truly enable decentralized manufacturing at commercialscale?
Pointing the way to future R&D success in rare indications
14.00Flexible, off the shelf vs. bespoke solutions? Unit operationsversus all-in-one? Can we define ‘best practices’ for the futuredevelopment of each?Dr Isabelle Riviere, Director, Michael G. Harris Cell Therapy & CellEngineering Facility,Memorial Sloan Kettering Cancer CenterDonna Rill, Vice President of Manufacturing,Cell MedicaKenny Choi, Head of Process Development & Tech Transfer,Mustang BioDr Don Healey, Senior Vice President, Operations,KBIBiopharmaDr John Sharpe, Chief Technology Officer, Cytonome
Session continues
15.30Close of Phacilitate Cell & Gene Therapy World 2018
Cord Blood & Perinatal Stem Cells Track see page 16
Cord Blood & Perinatal Stem Cells Track see page 16
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:23 Page 16
AGENDA
www.cellandgenetherapyworld.com
CORD BLOOD & PERINATAL STEM CELLS
• Macro trends in investor, pharma and regulatory environments- Investor and pharma perspectives – how/where will we seek toengage in the cord blood and perinatal stem cell field in future?
- Global regulatory development updates: will recent evolution ofguidelines and legislation (eg, in China) translate to perinatal stem cellbanking and application opportunities?
• Analyzing evolving pubic and family cord blood and perinatal stemcell banking business models worldwide
- What do ongoing public-private convergence and M&A trends, andthe continuing development of hybrid business models, mean for therobustness of the banking sector globally?
- What is the relative health of the sector – and what are the emergingdominant business models – in North America, South America, Europeand Asia?
- The search for sustainability - weighing up the viability of emergingrevenue streams: how are banks, biotechs and tool/service providersinnovating to both realize and monetize the potential of cord blood &perinatal stem cells?
- Beyond the cord – how diversification into the wider biobanking arenais presenting new, sustainable business opportunities.
Business Models & Investment: WEDNESDAY, JANUARY 24TH
• Clinical updates: examining trial designs and the latest data forproduct candidates based on cord blood and perinatal stem cells
- Case studies: what is the latest evidence of therapeutic potential inspecific indications? (Cardiovascular diseases, autism, hypoxicischemic encephalopathy, etc.)
- What is the regulatory pathway for these candidates to marketapproval and ultimately, to patients?
- Perinatal stem cells vs. bone marrow-derived cells – what have beenthe outcomes from comparative studies to date?
- What are the future modalities and therapeutic areas/diseaseapplications to target? (Eg. Engineered perinatal cells)
• What progress in alleviating the cord blood & perinatal cell expansionbottleneck?
- Troubleshooting manufacture of perinatal cell and tissue-derived MSCs- How to enable closed transitions between cell selection, cellexpansion and cell harvesting unit operations?
- How to address the current shortfalls in testing guidance andavailable, fit-for-purpose assays?
- Closing roundtable discussion: How would we approach commercialscale up of a dedicated cord blood & tissue bioprocessing facility?(Where to start: small but scalable? Straight to full scale? Modular?)
Clinical Applications & Cell Expansion:THURSDAY, JANUARY 25TH
• Jakub Baran, CEO & COO, Famicord Group, PolskiBank Komórek Macierzystych S.A.
• Greg Bonfiglio, Founder & Managing Partner,Proteus, LLC
• Dr John E. Davies, Professor, University of Toronto;President, Tissue Regeneration Therapeutics, Inc
• Dr Colleen Delaney, Founder and Chief MedicalOfficer, Nohla Therapeutics
• Dr Steve Elliman, CSO,Orbsen Therapeutics, Ltd
• Dorit Harati, Vice President, Quality Assurance,Manufacturing & Logistics, Gamida Cell
• Cade Hildreth, BS, MS, President & CEO,BioInformant.com
• Dr Karine Kleinhaus, Divisional Vice President,North America, Pluristem Therapeutics
• Dr Wolfgang Knirsch, CEO,Vita 34 AG
• Dr Joanne Kurtzberg, Director, Carolinas CordBlood Bank At Duke University; President,Cord BloodAssociation
• Dr Yijia Li, Director, Shunxi Regenerative Medicine,Yunnan Province Stem Cell Bank
• Todd McAllister, PhD, Executive Director,AmnionFoundation
• Dr Beth Shaz, Chief Medical & Scientific Officer, NewYork Blood Center
• Elizabeth J. Shpall, MD, Professor, Howard and LeeSmith Chair in Cancer Research; Director, Cell TherapyLaboratory and Cord Blood Bank; Deputy-Chair,Department Stem Cell Transplantation and CellularTherapy,University of Texas MD AndersonCancer Center
• Frances Verter, PhD, Founder & Director, Parent'sGuide to Cord Blood Foundation & CellTrials.org
SPEAKERS INCLUDE:
For full conference agenda www.cellandgenetherapyworld.com/agenda
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 17
AGENDA
www.cellandgenetherapyworld.com
• Facing up to critical raw materials supply shortfalls – the singlelargest elephant in the commercial cell & gene therapy room?
- Where specifically do/will the greatest shortfalls current exist and justhow significant are they in the context of expected clinical andcommercial demand over the short- to mid-term? (Eg. plasmids, cellculture media)
- How to develop the innovation and infrastructure needed toovercome raw material supply shortages whilst minimizing Cost ofGoods? (Eg. capitalizing on novel/emerging cell sources for the celltherapy industry)
• Starting material optimization for autologous and allogeneic cell &gene therapies
- Viral safety considerations for cell- and gene-based therapies- How to manage and standardize global/multi-site apheresis?Addressing quality and consistency challenges
- Defining best practice in allogeneic cell therapy donor supply andmanagement
• How to maximize efficiency in raw and starting materials qualitycontrol/characterization?
- Optimizing quality of raw and starting materials – what exactlyconstitutes ‘good enough’?
- Identifying and overcoming key challenges in raw and startingmaterials management for decentralized/point of care manufacturing(eg. of a CAR T cell immunotherapy)?
Raw & Starting Materials: TUESDAY, JANUARY 23RD
• Supply chain data management and integration - Integrated approach to management of CGT product supply chain- How to identify the data that is really critical to collect, and how tointegrate and utilize it to the benefit of the overall supply chain?
- Scaling up to commercial: how to automate the data managementpiece to allow the move from hundreds to thousands of patients?
- Track and trace and supply chain security – how to satisfy disparateregulatory requirements and standards on a multinational basis?
- Generic ‘off the shelf’ vs. tailored cell therapy supply chainmanagement software – analysing the practical utility/applicability ofboth options
• Tour of the Vein-to-Vein Supply Chain HubThis session will be staged in our expanded Supply Chain hub – anexperiential, circular journey along the entirety of the autologous cell-basedtherapy supply chain: from starting material obtainment/managementthrough cold chain logistics, bioprocessing, quality control, fill-finish andmanagement/ delivery to the patient back at the point of care.- Delivering a strategic roadmap for supply chain development andvalidation for patient-specific cell & gene therapies
- How to identify/predict and minimize the potential variables in yoursupply chain to achieve true consistency in product quality anddelivery?
- Leveraging supply chain strategies and technology to scale fromclinical to commercial volumes
• Supply chain scale up strategies and enabling technologies tominimize CoGs
- Sector leaders’ tips for designing and implementing efficient, scalablecell & gene supply chains
- Next generation cold chain technologies (including automated/closedsolutions) – what real improvements are they delivering in practice?(Eg. cost, quality, configurability, flexibility and ease of integration)
Cold Chain & Data Integration/Management:WEDNESDAY, JANUARY 24TH
• Stefano Baila, PhD, Director of Operations &Business Development,Holding F.I.S.
• Shirley Bartido, PhD, MBA, Director, RegulatoryAffairs, Cellectis
• Simon Ellison, Cell and Gene Therapy ServiceDirector, World Courier
• Timothy C. Fong, PhD, MBA, Vice President, Science& Technology, AllCells
• Marlin Frechette, Director, RegulatoryAffairs/Quality Systems, Management Representative,Irvine Scientific
• Anna Gilbert, Director, Quality Assurance, NohlaTherapeutics, Inc
• Amy Hines, Senior Manager, Apheresis & CollectionCenter Network Development, Be The MatchBiotherapies
• Louis Juliano, Senior Vice President, Global Sales &Business Development, HemaCare Corporation
• Thomas R. Kreil, PhD, Associate Professor ofVirology, Head of Pathogen Safety, Shire
• John Lunger, Vice President, Manufacturing & SupplyChain, Adaptimmune
• Timothy Moore, Executive Vice President ofTechnical Operations,Kite Pharma
• Scott Ohanesian, Senior Vice President ofCommercial Operations, Clinical Trial Logistics,QuickSTAT, A Quick Company
• Peter Olagunju, Senior Director, TechnicalOperations, bluebird bio
• Akshay Peer, PhD, Vice President of Sales & AccountManagement, TrakCel
• Robert Piperno, QA Director, Cell & Gene Therapies,GlaxoSmithKline
• Dr Alan K. Smith, Executive Vice President, TechnicalOperations,Bellicum Pharmaceuticals
• Adam Villa, Director, Clinical Product Logistics,CRISPR Therapeutics
• Claudia Zylberberg, PhD, CEO, Akron Biotech
SPEAKERS INCLUDE:
For full conference agenda www.cellandgenetherapyworld.com/agenda
SUPPLY CHAIN FOR ADVANCED THERAPIES
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 18
www.cellandgenetherapyworld.com
JAPANESEPARTNERING
LUNCHThis dedicated networkingsession delivers a uniqueopportunity to enable newpartnerships and discussionswith attendees from Japan
Expanding on the success of last year's cord blood track, this year will feature a
new and improved stream
T
Pha Insight collabor pion
highligh path to
PHACILITATETRAINING
Having an adequately skilled workforce hasbeen identified as a major speed-bump toindustrialisation, and as we see more
practitioners join from adjacent sectors, youtold us it was important to learn new and
important skills.
Call us on +44 207 384 7993 to find out moreabout our CPD accredited training day!
SUPPLY CHAIN &LOGISTICS HUB
CORD BLOOD& PERINATALSTEM CELLS
After 2017’s successful launch, we and ourpartners are teaming up together to empower
cell therapy developers to handle thecomplexities of a modern supply chain.
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 19
www.cellandgenetherapyworld.com
TranslationAcademy
Phacilitate and Cell and Gene TherapyInsights have teamed up to further supportcollaboration between academic and industrypioneers. The Translation Academy will
highlight promising innovation and support itspath to commercial success, focusing on the
themes of:• Financing
• Manufacturing• Regulatory
• Reimbursement
Yacht PartyOur legendary yacht party returns biggerand better than before for 2018! Ticketsare limited and will be allocated on a firstcome, first served basis so don't miss out!
THE BRAND NEWBIOPROCESS HUB......will highlight the cutting edge solutionsavailableacross harvesting, cell expansion,purification, sorting and QA/QC. Also join
MaSTherCell for a virtual reality walk through ofaGMP facility from the future!
Co-location with CELL & GENE
THERAPY World WorldStem Cell Summit
The only I-O event co-located with the leading Celland Gene Therapy and translational stem cell globalmeeting. Providing access to the most commerciallyadvanced technical expertise specifically for cellularimmunotherapies. As a combined event we will have1,200+ attendees, 200+ speakers, 100+ exhibitors –it is the one meeting on the global calendar attendedby all of the critical decision-makers from bothinside and outside of the cell & gene therapy/
immuno-oncology industry.
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 20
SPONSORS
Platinum sponsor
Gold Sponsors
Silver Sponsors
Bronze Sponsors
www.cellandgenetherapyworld.com
®
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 21
www.cellandgenetherapyworld.com
Indulge in the spirit of the city when you stay at thisdowntown Miami hotel. With its striking whitetowers overlooking the Miami River, Hyatt RegencyMiami is a landmark hotel offering first rate service,expansive meeting space, and the most convenientlocation in the area. You’ll enjoy easy access topopular attractions, like Brickell City Center,Wynwood Art District, Coral Gables, the Port ofMiami, and the Latin flavor of Little Havana.
· Refreshed rooms with views: Enjoy gorgeousviews of the river and bay in our refreshedguestrooms and suites with Hyatt Grand Bedsand free Wi-Fi
· Close to many attractions: Unmatched locationwith easy access to an incredible selection of artsand entertainment
· Quintessential Miami dining experiences:Discover endless dining options for every mealwith fresh, locally-sourced food at our hotel
Book your room online at cellandgenetherapyworld.com/about/venue and save with our exclusive delegate rate!
Hyatt Regency Miami
BISCAYNE BLVD WAY
SOU
TH
EA
ST 2
ND
AV
E
SOU
TH
WES
T 2
ND
AV
E
I-395
I-9
5
MIA
MI A
VE
Adrienne Arsht Centerfor the Performing Arts
American Airlines Arena
Venue
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 22
SUPER EARLY BIRD
Ends Friday 20th Oct
Delegate Type Rates
Pharma/Biotech $2,595
Technology/Service Provider $3,995
Academic/Government/Not-for-Profit $1,195
EARLY BIRD
Ends Friday 1st Dec
Delegate Type Rates
Pharma/Biotech $2,695
Technology/Service Provider $3,995
Academic/Government/Not-for-Profit $1,395
FULL RATE
Delegate Type Rates
Pharma/Biotech $2,895
Technology/Service Provider $3,995
Academic/Government/Not-for-Profit $1,595
TOP 10 TOPICS AT CELL & GENE THERAPY WORLD 2018
HOW TO REGISTER
Head to www.cellandgenetherapyworld.com to register now for our early bird rates, saving you $$$’s!
FOR INFORMATION ON:Small company rates • Group discounts • 1-day attendance ratePlease email [email protected] or call +44 (0)20 7384 7993
1. 21st Century Cures and the RMAT Designation; one year on, how has it been implemented?
6. Investor insights: How to safeguardagainst the threat of becoming
technologically obsolete in today’s ‘next-gen’ environment?
2. Exploring monetization models forcurative therapies: what are the viable
models in payers’ eyes today?
7. How to rationalize QC for commercial scale?
3. How to address questions and challenges around gene expression
longevity/control, immunogenicity and re-dosing in in vivo gene therapy?
8. How to identify the data that is reallycritical to collect, and how to integrateand utilize it to the benefit of the overall
supply chain?
4. Beyond AML: What is being done toovercome solid tumor resistance to
cellular immunotherapies?
9. What do ongoing public-privateconvergence and M&A trends, and the
continuing development of hybrid businessmodels, mean for the robustness of theCord Blood banking sector globally?
5. Optimizing quality of raw and starting materials – what exactlyconstitutes ‘good enough’?
10. How to truly enable decentralizedmanufacturing at commercial scale?
20276 CGT Miami Main Brochure V2.qxp_Layout 1 18/10/2017 16:24 Page 23